MicroRNA-34a: Role in cancer and cardiovascular disease

Current Drug Targets

Volumn 15, Issue 4, 2014, Pages 361-373

  Chen, Xi ^a   Zhou, Jian Ya ^a   Zhou, Jian Ying ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cardiovascular diseases; microRNA 34a; Molecular target therapy; Neoplasms

Indexed keywords

BORTEZOMIB; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MICRORNA 122; MICRORNA 34A; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; NOTCH1 RECEPTOR; NOTCH4 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; PROTEIN P63; SCATTER FACTOR RECEPTOR; SIRTUIN 1; SOMATOMEDIN C; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER INHIBITION; CANCER PROGNOSIS; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; DNA DAMAGE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; MICROARRAY ANALYSIS; NEOPLASM; NONHUMAN; ONCOGENE C MYB; ONCOGENE C MYC; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANIMALS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84896353799     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140120102935     Document Type: Review

References (132)

1. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11(3): 228-34.
2. Chekulaeva M, Filipowicz W. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 2009; 21(3): 452-60.
3. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1): 92-105.
4. Tarasov V, Jung P, Verdoodt B, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6(13): 1586-93.
5. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7(16): 2591-600.
6. Yin D, Ogawa S, Kawamata N, et al. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 2013; 32(9): 1155-63.
7. Cole KA, Attiyeh EF, Mosse YP, et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008; 6(5): 735-42.
8. Chen X, Hu H, Guan X, et al. CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer 2012; 130(7): 1607-13.
9. Vogt M, Munding J, Gruner M, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011; 458(3): 313-22.
10. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447(7148): 1130-4.
11. Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 2012; 26(2): 79-86.
12. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumorsuppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007; 104(39): 15472-7.
13. Weeraratne SD, Amani V, Neiss A, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 2011; 13(2): 165-75.
14. Christoffersen NR, Shalgi R, Frankel LB, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 2010; 17(2): 236-45.
15. Pulikkan JA, Peramangalam PS, Dengler V, et al. C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 2010; 116(25): 5638-49.
16. Agostini M, Tucci P, Killick R, et al. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci USA 2011; 108(52): 21093-8.
17. Ichimura A, Ruike Y, Terasawa K, Shimizu K, Tsujimoto G. MicroRNA-34a inhibits cell proliferation by repressing mitogenactivated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells. Mol Pharmacol 2010; 77(6): 1016-24.
18. Baer C, Claus R, Frenzel LP, et al. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res 2012; 72(15): 3775-85.
19. Siemens H, Jackstadt R, Hunten S, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelialmesenchymal transitions. Cell Cycle 2011; 10(24): 4256-71.
20. Peurala H, Greco D, Heikkinen T, et al. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. PLoS One 2011; 6(11): e26122.
21. Antonini D, Russo MT, De Rosa L, Gorrese M, Del Vecchio L, Missero C. Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol 2010; 130(5): 1249-57.
22. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40(1): 43-50.
23. Ikeda Y, Tanji E, Makino N, Kawata S, Furukawa T. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Mol Cancer Res 2012; 10(2): 259-69.
24. Nanni S, Aiello A, Re A, et al. Estrogen-Dependent Dynamic Profile of eNOS-DNA Associations in Prostate Cancer. PLoS One 2013; 8(5): e62522.
25. Iekushi K, Seeger F, Assmus B, Zeiher AM, Dimmeler S. Regulation of cardiac microRNAs by bone marrow mononuclear cell therapy in myocardial infarction. Circulation 2012; 125(14): 1765-73, S1761-7.
26. Roggli E, Britan A, Gattesco S, et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 2010; 59(4): 978-86.
27. Silber J, Jacobsen A, Ozawa T, et al. miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One 2012; 7(3): e33844.
28. Yang P, Li QJ, Feng Y, et al. TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 2012; 22(3): 291-303.
29. Gueta K, Molotski N, Gerchikov N, et al. Teratogen-induced alterations in microRNA-34, microRNA-125b and microRNA-155 expression: correlation with embryonic p53 genotype and limb phenotype. BMC Dev Biol 2010; 10: 20.
30. Nakatani F, Ferracin M, Manara MC, et al. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 2012; 226(5): 796-805.
31. Li L, Yuan L, Luo J, Gao J, Guo J, Xie X. MiR-34a inhibits proliferation and migration of breast cancer through downregulation of Bcl-2 and SIRT1. Clin Exp Med 2013; 13(2):109-17.
32. Osawa S, Shimada Y, Sekine S, et al. MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett 2011; 2(4): 613-9.
33. Wu J, Wu G, Lv L, et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis 2012; 33(3): 519-28.
34. Asslaber D, Pinon JD, Seyfried I, et al. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 2010; 115(21): 4191-7.
35. Gallardo E, Navarro A, Vinolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009; 30(11): 1903-9.
36. Ma Y, Qin H, Cui Y. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochem Biophys Res Commun 2013; 441(4): 958-63.
37. Wu X, Zhong D, Gao Q, Zhai W, Ding Z, Wu J. MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether a go-go 1 Expression. Int J Med Sci 2013; 10(6): 676-82.
38. Sempere LF, Preis M, Yezefski T, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010; 16(16): 4246-55.
39. Corney DC, Hwang CI, Matoso A, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010; 16(4): 1119-28.
40. Li Y, Guessous F, Zhang Y, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009; 69(19): 7569-76.
41. Gao H, Zhao H, Xiang W. Expression level of human miR-34a correlates with glioma grade and prognosis. J Neurooncol 2013; 113(2): 221-8.
42. Subramanian S, Thayanithy V, West RB, et al. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 2010; 220(1): 58-70.
43. Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009; 275(1): 44-53.
44. Kumar B, Yadav A, Lang J, Teknos TN, Kumar P. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One 2012; 7(5): e37601.
45. Shen Z, Zhan G, Ye D, et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol 2012; 29(4): 2473-80.
46. Yan D, Zhou X, Chen X, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci 2009; 50(4): 1559-65.
47. Rucker FG, Russ AC, Cocciardi S, et al. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance. Leukemia 2013; 27(2): 353-61.
48. Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Eur J Endocrinol 2013; 168(5): 675-81.
49. Fang C, Zhu DX, Dong HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 2012; 91(4): 553-9.
50. Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol 2012; 106(8): 947-52.
51. Navarro A, Clot G, Prieto M, et al. MicroRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clin Cancer Res 2013; 19(12): 3121-9.
52. Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47(5): 784-91.
53. Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica 2013. [Epub ahead of print].
54. Patel D, Boufraqech M, Jain M, et al. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. Surgery 2013; 154(6): 1224-9.
55. Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexedbased chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 2014; 229(1): 97-9.
56. Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008; 582(10): 1564-8.
57. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9(11): 785-97.
58. He C, Xiong J, Xu X, et al. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 2009; 388(1): 35-40.
59. Kumar B, Yadav A, Lang J, Teknos TN, Kumar P. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One 2012; 7(5): e37601.
60. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26(34): 5017-22.
61. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell death and differentiation 2011; 18(9): 1414-24.
62. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4(8): e6816.
63. Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann NY Acad Sci 2012; 1271: 10-19.
64. Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377(1): 114-9.
65. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105(36): 13421-6.
66. Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 2012; 130(11): 2526-38.
67. Luan S, Sun L, Huang F. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251. Arch Med Res 2010; 41(2): 67-74.
68. Tan J, Fan L, Mao JJ, et al. Restoration of miR-34a in p53 deficient cells unexpectedly promotes the cell survival by increasing NFkappaB activity. J Cell Biochem 2012; 113(9): 2903-8.
69. Dang CV. MYC on the path to cancer. Cell 2012; 149(1): 22-35.
70. Yamamura S, Saini S, Majid S, et al. MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis 2012; 33(2): 294-300.
71. Yamamura S, Saini S, Majid S, et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One 2012; 7(1): e29722.
72. Sotillo E, Laver T, Mellert H, et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011; 30(22): 2587-94.
73. Wei JS, Song YK, Durinck S, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27(39): 5204-13.
74. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16(11): 2985-95.
75. Jung KH, Park BH, Hong SS. Progress in cancer therapy targeting c-Met signaling pathway. Arch Pharm Res 2012; 35(4): 595-604.
76. Yan K, Gao J, Yang T, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One 2012; 7(3): e33778.
77. Shao H, Huang Q, Liu ZJ. Targeting Notch signaling for cancer therapeutic intervention. Adv Pharmacol 2012; 65: 191-234.
78. Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y, Sarkar FH. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res 2012; 4(4): 432-42.
79. Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH, Gupta SV. Deltatocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer 2012; 131(11): 2668-77.
80. Li WB, Ma MW, Dong LJ, Wang F, Chen LX, Li XR. MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. Cancer Biol Ther 2011; 12(6): 477-83.
81. Bu P, Chen KY, Chen JH, et al. A microRNA miR-34a-Regulated Bimodal Switch Targets Notch in Colon Cancer Stem Cells. Cell Stem Cell 2013; 12(5): 602-15.
82. Pang RT, Leung CO, Lee CL, et al. MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of Delta-like1. BMC Cancer 2013; 13: 25.
83. de Antonellis P, Medaglia C, Cusanelli E, et al. MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumorpropagating cells and supports neural differentiation in medulloblastoma. PLoS One 2011; 6(9): e24584.
84. Pang RT, Leung CO, Ye TM, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010; 31(6): 1037-44.
85. Herr P, Hausmann G, Basler K. WNT secretion and signalling in human disease. Trends Mol Med 2012; 18(8): 483-93.
86. Kim NH, Kim HS, Kim NG, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal 2011; 4(197): ra71.
87. Yang SH, Sharrocks AD, Whitmarsh AJ. MAP kinase signalling cascades and transcriptional regulation. Gene 2013; 513(1): 1-13.
88. Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, Stallings RL. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 2011; 11: 33.
89. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 2013; 4(9): 1399-415.
90. Zhao G, Guo J, Li D, et al. MicroRNA-34a Suppresses Cell Proliferation by Targeting LMTK3 in Human Breast Cancer MCF-7 Cell Line. DNA Cell Biol 2013; 32(12): 699-707.
91. Zhao J, Lammers P, Torrance CJ, Bader AG. TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther 2013; 21(9): 1678-86.
92. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 2011; 130(2): 663-79.
93. Yang S, Li Y, Gao J, et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 2012; 32(36): 4294-303.
94. Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Muller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 2012; 26(11): 2421-4.
95. Ostling P, Leivonen SK, Aakula A, et al. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011; 71(5): 1956-67.
96. Vo DT, Qiao M, Smith AD, Burns SC, Brenner AJ, Penalva LO. The oncogenic RNA-binding protein Musashi1 is regulated by tumor suppressor miRNAs. RNA Biol 2011; 8(5): 817-28.
97. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 2011; 6(8): e24099.
98. Heinemann A, Zhao F, Pechlivanis S, et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012; 72(2): 460-71.
99. Zhao H, Ma B, Wang Y, et al. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncol Rep 2013; 29(3): 1027-36.
100. Duan W, Xu Y, Dong Y, Cao L, Tong J, Zhou X. Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway. J Radiat Res 2013; 54(4): 611-9.
101. Schultz N, Marenstein DR, De Angelis DA, et al. Off-target effects dominate a large-scale RNAi screen for modulators of the TGFbeta pathway and reveal microRNA regulation of TGFBR2. Silence 2011; 2: 3.
102. Kim NH, Cha YH, Kang SE, et al. p53 regulates nuclear GSK-3 levels through miR-34-mediated Axin2 suppression in colorectal cancer cells. Cell Cycle 2013; 12(10): 1578-87.
103. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17(2): 211-5.
104. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010; 70(14): 1501-12.
105. Kastl L, Brown I, Schofield AC. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 2012; 131(2): 445-54.
106. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 2011; 300(2): 197-204.
107. Cao W, Fan R, Wang L, et al. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol 2013; 34(2): 963-71.
108. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266.
109. Yang F, Li QJ, Gong ZB, et al. MicroRNA-34a Targets Bcl-2 and Sensitizes Human Hepatocellular Carcinoma Cells to Sorafenib Treatment. Technol Cancer Res Treat 2013.
110. Craig VJ, Cogliatti SB, Imig J, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011; 117(23): 6227-36.
111. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011; 30(25): 2888-99.
112. Boon RA, Iekushi K, Lechner S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013; 495(7439): 107-10.
113. Lin RC, Weeks KL, Gao XM, et al. PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol 2010; 30(4): 724-32.
114. Bernardo BC, Gao XM, Winbanks CE, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci USA 2012; 109(43): 17615-20.
115. Fan F, Sun A, Zhao H, et al. MicroRNA-34a Promotes Cardiomyocyte Apoptosis Post Myocardial Infarction Through Down-regulating Aldehyde Dehydrogenase 2. Curr Pharm Des 2013; 19(27): 4865-73.
116. Peng X, Shao J, Shen Y, et al. FAT10 protects cardiac myocytes against apoptosis. J Mol Cell Cardiol 2013; 59C: 1-10.
117. Xu Q, Seeger FH, Castillo J, et al. Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease. J Am Coll Cardiol 2012; 59(23): 2107-17.
118. Shan Z, Yao C, Li ZL, et al. Differentially expressed microRNAs at different stages of atherosclerosis in ApoE-deficient mice. Chin Med J (Engl) 2013; 126(3): 515-20.
119. Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun 2010; 398(4): 735-40.
120. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res 2007; 100(1): 15-26.
121. Zhao T, Li J, Chen AF. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am J Physiol Endocrinol Metab 2010; 299(1): E110-6.
122. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368(18): 1685-94.
123. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012; 11(11): 860-72.
124. Shi S, Han L, Gong T, Zhang Z, Sun X. Systemic Delivery of microRNA-34a for Cancer Stem Cell Therapy. Angew Chem Int Ed Engl 2013; 52(14): 3901-5.
125. Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18(22): 6260-70.
126. Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70(14): 5923-30.
127. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011; 19(6): 1116-22.
128. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010; 18(9): 1650-6.
129. Tivnan A, Orr WS, Gubala V, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using antidisialoganglioside GD2 coated nanoparticles. PLoS One 2012; 7(5): e38129.
130. Hu QL, Jiang QY, Jin X, et al. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 2013; 34(9): 2265-76.
131. Li L, Xie X, Luo J, et al. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther 2012; 20(12): 2326-34.
132. Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011; 10(8): 1470-80.